ON THE MOVE:Gilead Sciences on a Roll
Biotech reports huge Q2 earnings jump, gains FDA approval and EU nod for new cancer drug.
Gilead Sciences, the biotech company at the center of the growing controversy over the high price of specialty drugs, gave investors two reasons to cheer. Besides reporting second-quarter 2014 revenue of $6.53 billion, more than double the $2.77 billion in revenue in the same period last year, the U.S. Food and Drug Administration approved the Foster City, California-based biotech’s cancer drug Zydelig for three blood cancers. Read More